BML Inc.
Financial Results
Presentation for Fiscal 2020
May 13, 2021
Kensuke Kondo,
President and
Representative Director
Overview of Fiscal 2020
Financial Results
2
10-Year Earnings History
Novel coronavirus PCR tests contributing to increases in both
sales and income
(Millions of yen)
FY2020
3
Year-on-Year Comparison
(Millions of yen) | ||||
FY2019 | FY2020 | Year on | Change | |
year | ||||
Net sales | 120,732 | 138,571 | 17,839 | 14.8% |
Testing business | 115,022 | 132,911 | 17,888 | 15.6% |
Clinical testing business | 110,113 | 128,612 | 18,498 | 16.8% |
Other testing business | 4,908 | 4,299 | (609) | (12.4)% |
Medical informatics business | 4,202 | 4,214 | 12 | 0.3% |
Other businesses | 1,507 | 1,445 | (61) | (4.1)% |
Operating income | 9,763 | 19,936 | 10,172 | 104.2% |
Ordinary income | 10,211 | 20,803 | 10,592 | 103.7% |
Profit attributable to owners of | 6,375 | 13,711 | 7,336 | 115.1% |
parent | ||||
4
Breakdown of Changes in Sales by Business Segment
Net sales up ¥17,839m (14.8%) YoY
(Millions of yen)
609 | 49 | |
138,571 | ||
18,498 | Food hygiene | Medical |
business, etc. | informatics | |
+17,839 | business, | |
Clinical testing | other businesses | |
business |
120,732
5
This is an excerpt of the original content. To continue reading it, access the original document here.
Attachments
- Original document
- Permalink
Disclaimer
BML Inc. published this content on 13 May 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 03 June 2021 00:24:00 UTC.